Influence of neuromelanin on oxidative pathways within the human substantia nigra

Neurotoxicology and Teratology

Volumn 24, Issue 5, 2002, Pages 621-628

  Double, K L ^a   Ben Shachar, D ^b   Youdim, M B H ^b   Zecca, L ^c   Riederer, P ^d   Gerlach, M ^d  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c CNR   (Italy)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Human; Iron; Neuromelanin; Oxidative stress; Parkinson's disease; Substantia nigra

Indexed keywords

FREE RADICAL; IRON; METAL; NEUROMELANIN;

ATTENUATION; BRAIN TISSUE; CELL DAMAGE; CELL DEATH; CHELATION; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; REVIEW; SUBSTANTIA NIGRA; TISSUE LEVEL;

BINDING SITES; CELL RESPIRATION; DOPAMINE; FREE RADICALS; HUMANS; IRON; MELANINS; NEURONS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

PARKINSONIA;

EID: 0036719084     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(02)00218-0     Document Type: Review

References (67)

1. EPR investigations of the iron domain in neuromelanin
2. 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson's disease
3. Nuclear magnetic resonance spectroscopy characterization and iron content determination of human mesencephalic neuromelanin
4. Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons
5. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease
6. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease
7. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography
8. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease
9. Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction
10. Nigral and extanigral pathology in Parkinson's disease
11. Sequestration of iron by Lewy bodies in Parkinson's disease
12. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease
13. A quantitative analysis of isoferritins in select regions of aged, parkisonian and Alzheimer's diseased brains
14. Glutathione peroxidase, glial cells and Parkinson's disease
15. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia
16. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
17. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
18. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
19. The significance of neuromelanin in Parkinson's disease
20. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins
21. Impaired iron homeostasis in Parkinson's disease
22. The motor circuit of the human basal ganglia reconsidered
23. Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice
24. Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits
25. Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra
26. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrastriatal projections and differential neuron susceptibility in Parkinson's disease
27. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study
28. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease
29. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy
30. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease
31. Reactive oxygen species and the central nervous system
32. The ferritins: Molecular properties, iron storage function and cellular regulation
33. Time course of dopaminergic cell death and changes in iron, ferritin and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning
34. Loss of thalamic intralaminar nuclei in progressive supranuclei palsy and Parkinson's disease
35. Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease
36. Iron-melanin complex in substantia nigra of parkinsonian brains: An X-ray microanalysis
37. Brain iron and ferritin in Parkinson's disease and Alzheimer's disease
38. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
39. The Haber-Weiss reaction and mechanisms of toxicity
40. Iron as a catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
41. Photoprotective actions of natural and synthetic melanins
42. Preservation of midbrain catecholaminergic neurons in very old human subjects
43. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
44. Excessive iron accumulation in the brain: A possible potential source of neurodegeneration in Parkinson's disease
45. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients
46. Oxidative stress hypothesis in Alzheimer's disease
47. Pigmentation in the nucleus substantia nigra of mammals
48. Increasing striatal iron content associated with normal aging
49. Rate of cell death in Parkinson's disease indicates an active neuropathological process
50. Iron-melanin complex is toxic to dopaminergic neurons in nigrostriatal co-culture
51. Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: Possible implications for the etiology of Parkinson's disease
52. Dopamine-melanin induces apoptosis in PC12 cells: Possible implications for the etiology of Parkinson's disease
53. The effect of melanin on iron associated decomposition of hydrogen peroxide
54. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
55. Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals
56. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease
57. Lipid peroxidation in pigmented and unpigmented liver tissues: Protective role of melanin
58. Oxidation of dopamine in the presence of cysteine: Characterization of new toxic products
59. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: An electron paramagnetic resonance spectroscopy study
60. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
61. On the function of neuromelanin
62. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
63. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkisonian African Green monkey: Evidence from proton microprobe elemental microanalysis
64. The enigma of neuromelanin in Parkinson's disease substantia nigra
65. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems
66. Iron, neuromelanin and ferritin content in substantia nigra of normal subjects at different ages. Consequences for iron storage and neurodegenerative processes
67. Total and paramagnetic metals in human substantia nigra and its neuromelanin